Catheter Precision Stock Price, News & Analysis

Catheter Precision (NYSE: VTAK) reported its Q1 2025 financial results and operational updates. Sales revenue increased 74% to $143,000 compared to $82,000 in Q1 2024. The company recorded a net loss of $4.0 million, with $1.2 million in non-cash charges. Key highlights include approximately 50 hospitals evaluating VIVO and LockeT devices, acquisition of Cardionomics' assets including their Cardiac Pulmonary Nerve Stimulation System, and PeriKard LLC acquisition. The company presented four abstracts at the Heart Rhythm Society Symposium, showing strong clinical results for both VIVO (94% accuracy rate) and LockeT devices. Post-quarter, VTAK secured a $1.5 million private placement from institutional investors. As of March 31, 2025, total assets were $24.8 million, with shareholders' equity at $7.9 million and cash position at $450,000.

Catheter Precision (VTAK) has secured a $1.5 million private placement equity financing and acquired promissory notes of QHSLab. The financing involves selling 1,500 shares of Series B Preferred Stock convertible into 4,287,000 common shares, along with 4,285,716 warrants at a $0.50 exercise price. Additionally, the company issued another 1,500 preferred shares to acquire QHSLab's senior secured notes worth approximately $1.6 million.

The strategic move aims to expand Catheter Precision's reach into general cardiology and cardiac electrophysiology with office-oriented product lines. QHSLab operates in physician marketplaces, offering diagnostic solutions for mental health, cardiology, drug compliance, and allergy analyses. Ladenburg Thalmann & Co. served as the exclusive placement agent for these transactions.

Catheter Precision (VTAK) has announced that its 82% owned subsidiary has acquired key heart failure assets from Cardionomic, Inc. The acquisition includes the CPNS System, an innovative therapy for treating acute decompensated heart failure (ADHF). The system uses electrical stimulation via a temporary catheter in the pulmonary artery to target heart failure's root cause by stimulating autonomic cardiac nerves. This technology addresses a significant medical need, as over 1 million Americans are hospitalized annually for ADHF, with patients facing high in-hospital morbidity, frequent rehospitalization, and subsequent death risks. Initial studies of the CPNS System have shown promising results. The acquisition follows a definitive agreement made with a Cardionomic assignor in April.

Catheter Precision (VTAK) presented new clinical data for their VIVO non-invasive mapping system at the 46th Annual Heart Rhythm Association Conference. The system, which identifies ventricular arrhythmia areas pre-procedure, has shown over 95% accuracy and reduces procedure time by nearly 30%. Leading physicians presented data highlighting key benefits: statistically significant improvements in procedural outcomes when used pre-procedurally, ability to identify arrhythmia sources in challenging cases, and high accuracy with successful long-term outcomes in ischemic ventricular tachycardia patients. The data is being prepared for submission to industry journals for detailed publications.

Catheter Precision (VTAK) announced its participation in the 46th annual Heart Rhythm Society (HRS) meeting from April 24-27, 2025, in San Diego. The conference will gather nearly 10,000 professionals in arrhythmia care and electrophysiology, featuring over 200 educational sessions and 3,400 scientific abstracts.

The company will present four research abstracts at HRS 2025: three for VIVO and one for LockeT. Key findings include:

• VIVO showed 94% accuracy in a 125 multi-center European study with 83% long-term procedural success
• Research demonstrating VIVO's effectiveness in mapping difficult-to-identify PVCs
• LockeT's safety and efficacy study in 139 patients for large-bore access procedures
• VIVO's 89% accuracy in predicting exit site locations for scar-dependent VT, with 86% of patients free from device therapy after one year

Catheter Precision (VTAK) has signed a definitive agreement to acquire assets related to the Cardiac Pulmonary Nerve Stimulation (CPNS) System through its 82% owned subsidiary, Cardionomix. The CPNS System, developed by Cardionomic, targets acute decompensated heart failure (ADHF) treatment through electrical stimulation via a temporary catheter.

The acquisition terms include 1,000,000 unregistered common stock shares and a $1.5 million three-year promissory note at 4% annual interest through Cardionomix. Initial clinical studies showed promising results, including reduced heart failure worsening, increased fluid loss, improved quality of life, and reduced mortality.

The technology addresses a market of approximately 1 million annual U.S. hospital admissions for heart failure, with potential annual revenues exceeding $1 billion. The Cleveland Clinic Foundation, Abbott Laboratories, and New Era Associates will receive economic interests in VTAK common stock and Cardionomix note as current creditors.

Catheter Precision (NYSE: VTAK), a US medical device company specializing in cardiac electrophysiology products, has made a mandatory public announcement under NYSE American Company Guide Section 610(b). The company disclosed that its audited financial statements for the year ended December 31, 2024, included an independent audit opinion containing a Substantial Doubt Regarding Going Concern paragraph.

This disclosure, previously included in the company's Annual Report on Form 10-K filed March 31, 2025, does not represent any changes or amendments to the consolidated financial statements or the annual report.

Catheter Precision (NYSE/American: VTAK) has received its first US patent allowance for the LockeT surgical closure device, designed for orthoscopic entry wounds. This adds to the company's existing international patents for LockeT in China, Europe, and the United Kingdom.

The company expects to receive the CE mark for LockeT in the current quarter, which will enable revenue generation in Europe. The product has been well-received since its US rollout in late last year, offering improved outcomes while reducing procedure costs in international markets.

Catheter Precision (NYSE American: VTAK) reported its Q4 and full-year 2024 financial results. The company's Q4 revenue reached $149,000, showing a 55% sequential increase from Q3, while full-year 2024 revenue totaled $420,000. Q4 net loss was $5.6 million, including $3.1 million in non-cash charges, with full-year net loss at $16.6 million.

Key operational highlights include: sequential growth in LockeT sales since Q2 2024, completion of CE Mark audits in Q4 2024 with anticipated approval in Q2 2025, and expansion of VIVO sales across multiple international markets. The company reported 26 institutions evaluating LockeT by year-end. Financial position shows total assets of $27.7 million and shareholders' equity of $11.8 million as of December 31, 2024, with 8,004,633 outstanding common shares.